Nagdeep Giri

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

A.R. Abdul Razak, Denis Soulières, Scott A. Laurie et al. · Annals of Oncology · 2012 · 103 citations

Oncology, Phase Ii Trial, Medicine +8

Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine

Guoyu Pan, Nagdeep Giri, William F. Elmquist · Drug Metabolism and Disposition · 2007 · 89 citations

P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution

Naveed Shaik, Nagdeep Giri, Guoyu Pan et al. · Drug Metabolism and Disposition · 2007 · 84 citations

Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design

Nagdeep Giri, Sagar Agarwal, Naveed Shaik et al. · Drug Metabolism and Disposition · 2008 · 82 citations · Full text

Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse

Nagdeep Giri, Naveed Shaik, Guoyu Pan et al. · Drug Metabolism and Disposition · 2008 · 68 citations · Full text